hsp90aa1.1

Overview

hsp90aa1.1 is a protein-coding target associated with the HSP90 family of molecular chaperones, specifically the Hsp90alpha axis referenced in recent biomedical studies. HSP90 proteins are central regulators of protein folding, stabilization, and client-protein maturation, and they are widely studied in cancer, inflammatory disease, and stress-response biology because many signaling proteins depend on HSP90-mediated chaperoning for functional stability.

In the recent literature provided, hsp90aa1.1 was investigated primarily as a therapeutic target rather than as a standalone diagnostic marker. The studies collectively suggest that HSP90/Hsp90alpha supports the stability of oncogenic and inflammatory client proteins such as PCNA, NLRP3, Akt1, and broader HSP90/PI3K/Akt/mTOR signaling components. This makes the protein relevant to tumor biology, inflammasome regulation, and stress-associated tissue injury, as well as to biomarker development and imaging of HSP90 expression in vivo.

Focus of Latest Publications

Recent publications have focused on hsp90aa1.1 as part of HSP90-targeted strategies across several disease contexts, especially cancer and inflammatory liver disease. In triple-negative breast cancer, bakuchiol was investigated as a natural HSP90-targeting lead using network pharmacology, molecular docking, molecular dynamics, a cell-free N-terminal HSP90 binding assay, and in vitro studies. The compound showed preferential cytotoxicity toward MDA-MB-231 cells, was identified as a competitive N-terminal HSP90 inhibitor, downregulated the HSP90 client protein EGFR, and increased HSP70 expression, consistent with HSP90 inhibition. It also showed anti-proliferative, pro-apoptotic, and anti-metastatic effects, and acted synergistically with doxorubicin.

In oral squamous cell carcinoma, integrative database-driven analyses identified HSP90AA1 and HSP90AB1 among the hub genes associated with poor survival, and linked their expression to PI3K/Akt/mTOR signaling. Hippeastrine was then evaluated through QSAR modeling, docking, molecular dynamics, and in vitro assays in CAL27 and SCC-9 cells. The compound suppressed cell viability, colony formation, migration, and invasion, and western blotting confirmed inhibition of the HSP90-PI3K-Akt-mTOR axis. Rescue with the PI3K activator 740 Y-P reversed the effects on viability and PI3K/Akt phosphorylation, supporting pathway involvement.

Other studies examined hsp90aa1.1 in combination or vulnerability-based settings. In a rat model of metabolic dysfunction-associated steatohepatitis, alvespimycin, an HSP90 inhibitor, combined with fluvastatin improved liver injury, dyslipidemia, oxidative imbalance, inflammasome activation, pyroptosis, and fibrosis more effectively than either agent alone. The combination reduced HSP90, NLRP3, caspase-1, NTGSDMD, and p-SMAD2/3, suggesting that HSP90 inhibition destabilized NLRP3 and contributed to suppression of the ox-LDL-NLRP3-caspase-1-IL-1β/IL-18 axis. In TP53-mutated AML with ribosomal gene loss, chemical screening identified HSP90 inhibition as a selective vulnerability in cases with low ribosomal protein gene expression, linking translational defects to sensitivity to HSP90-targeted intervention.

Additional publications extended HSP90-related work to imaging and target discovery. A novel labeled small-molecule inhibitor-based PET/SPECT tracer targeting HSP90 was developed to improve in vivo detection of tumor HSP90 expression, with enhanced uptake in colorectal and gastric cancer models and reduced liver and kidney retention. In retinal organoid screening, HSP90 inhibitors transiently protected cone photoreceptors but were harmful over longer periods, indicating context- and time-dependent effects. Finally, a screening study for PCNA-targeting compounds unexpectedly identified the Hsp90α inhibitor SNX-2112 as a ligand of PCNA, revealing a new chemical scaffold for PCNA-targeting inhibitor development.

Key Publications

NEWJun Exploring Bakuchiol as an HSP90-Targeting Lead Against Triple-Negative Breast Cancer: Evidence from In Silico, In Vitro, and Synergy Studies. (Journal of computer-aided molecular design, 2026, PMID 42334659): "The present study aims to investigate the potential of bakuchiol in mitigating triple-negative breast cancer (TNBC) by targeting heat shock protein 90 (HSP90), a pivotal molecular chaperone implicated in cancer cell growth and progression."
Jun Integrative Database-Driven In Silico and In Vitro Study of Anemarrhena asphodeloides Bunge Highlighting Hippeastrine as a Regulator of the HSP90/PI3K/Akt/mTOR Axis in Oral Squamous Cell Carcinoma. (Advanced biology, 2026, PMID 42216572): "...demonstrated stable binding of key bioactive compounds with HSP90 and AKT1, highlighting hippeastrine as a promising candidate."
May Disruption of upstream ox-LDL signaling and HSP90-mediated NLRP3 stability protects against experimental steatohepatitis. (Naunyn-Schmiedeberg's archives of pharmacology, 2026, PMID 42183856): "Mechanistically, the combination targets two distinct but converging levels of inflammasome regulation: FLU reduces ox-LDL, a key upstream activator of NLRP3, whereas ALV destabilizes the client protein NLRP3 by inhibiting its molecular chaperone HSP90."
May TP53-mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition. (Science advances, 2026, PMID 42139355): "Chemical screening identified HSP90 inhibition as a selective vulnerability in AML with low RPG expression."
May Design, Synthesis, and Evaluation of a Novel-Labeled Small Molecule Inhibitor-Based PET/SPECT Tracer Targeting HSP90. (Journal of medicinal chemistry, 2026, PMID 42076973): "However, their efficacy depends on tumor HSP90 expression levels, necessitating probes for subtype-specific detection in vivo."
Jun Licochalcone A from Ma-Xing-Shi-Gan decoction to prevent Asthma through the inhibition of ferroptosis CD4+ T Cell by GART/HSP90α signaling pathway. (International immunopharmacology, 2026, PMID 41967212): "Licochalcone A from Ma-Xing-Shi-Gan decoction to prevent Asthma through the inhibition of ferroptosis CD4+ T Cell by GART/HSP90α signaling pathway."
Mar Cell-type-focused compound screen in human organoids reveals CK1 inhibition protects cone photoreceptors from death. (Neuron, 2026, PMID 41916277): "We identified inhibitors of casein kinase 1 (CK1) that protected cones, heat shock protein 90 (HSP90) inhibitors that saved cones in the short term but damaged them in the longer term, and broad histone deacetylase (HDAC) inhibition by many compounds that significantly damaged cones."
Apr Screening for novel chemical scaffolds targeting PCNA identifies the Hsp90alpha inhibitor SNX-2112. (Current research in structural biology, 2026, PMID 41743503): "Notably, we discovered that the Hsp90α inhibitor, SNX-2112, binds to PCNA within the major PIP-box binding pocket, revealing a new chemical scaffold for the potential development of novel PCNA-targeting inhibitors."